What Is the GLOW Peptide Blend? GHK-Cu, TB-500 and BPC-157 Regeneration Stack Explained

Pep-Dose Staff

The GLOW blend is a research peptide combination that unites three powerful repair and regeneration agents – GHK-Cu (copper tripeptide), TB-500 (thymosin beta-4 fragment), and BPC-157 (body protection compound-157) – in a single 70 mg vial. Each component targets distinct but overlapping repair pathways: GHK-Cu drives collagen synthesis and matrix remodeling, TB-500 enables systemic cell migration and angiogenesis, and BPC-157 provides localized healing and anti-inflammatory signaling. Together, GLOW aims to accelerate tissue repair more comprehensively than any single peptide could achieve alone.

Composition: GLOW contains GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg in a single 70 mg lyophilized vial.

Fast Answer / Executive Summary

GLOW is a three-peptide blend designed for comprehensive tissue regeneration: GHK-Cu modulates collagen synthesis and genomic repair programs; TB-500 enables cell migration, systemic angiogenesis, and anti-fibrotic signaling; BPC-157 provides localized healing, VEGF upregulation, and gut protection. Each component has an independent evidence base in preclinical and – for GHK-Cu – limited human studies.

Core Concepts and Key Entities

Component 1: GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex)

GHK-Cu is a naturally occurring copper tripeptide that declines with age (from approximately 200 ng/mL in young adults to 80 ng/mL by age 60). It acts as both a copper chaperone and a genomic regulator, upregulating over 4,000 genes related to tissue repair, anti-oxidation, and anti-inflammation while downregulating genes linked to tissue destruction and chronic inflammation.

In GLOW, GHK-Cu provides:

  • Collagen I, III, and IV synthesis stimulation
  • Matrix metalloproteinase (MMP) and TIMP balance for healthy tissue remodeling
  • Angiogenesis and wound contraction support
  • NF-kB suppression for inflammation control

Component 2: TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a 7-amino acid synthetic fragment of thymosin beta-4 that binds G-actin to enable rapid cell migration into injury sites. It promotes systemic healing by driving endothelial progenitor cell recruitment, VEGF expression, and reduction of myofibroblast activity (limiting fibrosis).

Component 3: BPC-157 (Body Protection Compound-157)

BPC-157 is a 15-amino acid synthetic peptide derived from a gastric juice protective protein. It is extensively studied for localized repair of tendons, muscles, bone, ligaments, and gut tissue. Key mechanisms include FAK-paxillin pathway activation for tendon cell outgrowth, VEGF receptor upregulation, and normalization of the nitric oxide pathway to restore vascular function.

Why GHK-Cu dominates the ratio (50 mg vs. 10 mg each for TB-500 and BPC-157): GHK-Cu is dosed in milligrams (not micrograms) for systemic effects because it acts as both a peptide and a copper chaperone. Its higher mass contribution ensures adequate genomic modulation alongside the smaller but biologically potent quantities of TB-500 and BPC-157.

Step-by-Step: How to Work With GLOW

Step 1 – Reconstitute the 70 mg vial

Add 3.0 mL bacteriostatic water to the GLOW vial to yield approximately 23.3 mg/mL. At this concentration, 1 unit on a U-100 syringe = approximately 233 mcg total blend.

Step 2 – Follow the standard daily protocol

The standard research approach is 2,330 mcg (10 units = 0.10 mL) once daily, subcutaneously, for a 4-week cycle. Each injection delivers approximately 1.7 mg GHK-Cu + 330 mcg TB-500 + 330 mcg BPC-157.

For the full dosing table, reconstitution steps, and supply calculator, see the GLOW 70 mg Dosage Protocol.

Step 3 – Cycle and rest

A standard cycle is 4 weeks on (28 daily injections), followed by a 2-4 week off period to assess progress before considering another cycle.

Step 4 – Combine with lifestyle support

  • High-protein diet (1.6-2.2 g/kg/day) to support collagen and matrix synthesis
  • Adequate sleep (7-9 hours) for growth hormone-mediated repair
  • Vitamin C and zinc supplementation to support collagen cross-linking

Comparison and Alternatives

Blend Composition Key Addition Over Wolverine Stack Best For
Wolverine Stack BPC-157 + TB-500 – Acute musculoskeletal repair
GLOW GHK-Cu + TB-500 + BPC-157 GHK-Cu for collagen, matrix, anti-aging skin Multi-tissue repair + skin rejuvenation
KLOW GHK-Cu + TB-500 + BPC-157 + KPV KPV for gut and immune anti-inflammation GLOW benefits + gut/immune involvement

FAQs

1) What is the GLOW blend? GLOW is a research peptide blend of GHK-Cu (50 mg), TB-500 (10 mg), and BPC-157 (10 mg) designed for comprehensive tissue regeneration. Each component targets different healing pathways – matrix remodeling, cell migration, and localized repair – in one convenient vial.

2) How is GLOW different from just taking BPC-157 and TB-500? GLOW adds GHK-Cu to the standard Wolverine Stack (BPC-157 + TB-500). GHK-Cu contributes copper-dependent collagen synthesis, genomic modulation of 4,000+ repair genes, and anti-aging skin benefits that BPC-157 and TB-500 alone do not provide.

3) What is the GLOW dosage? The standard daily dose is 2,330 mcg (10 units = 0.10 mL) once daily from a 3.0 mL reconstituted 70 mg vial. One vial provides a full 28-day cycle at this dose. Full protocol details are at the GLOW 70 mg Dosage Protocol.

4) Is GLOW good for skin? The GHK-Cu component has the strongest evidence for skin benefit – human data exists for wound healing, post-laser resurfacing recovery, and collagen stimulation. TB-500 and BPC-157 also contribute angiogenesis and anti-inflammatory effects that support dermal repair.

5) How long does a GLOW cycle last? The standard research protocol is 4 weeks (28 daily injections) from one 70 mg vial, followed by a 2-4 week rest period. Multiple cycles may be appropriate depending on the recovery goal.

6) What is the difference between GLOW and KLOW? KLOW adds KPV (a tripeptide with potent gut and immune anti-inflammatory effects) to the GLOW formula. This makes KLOW a preferred option when gut inflammation, IBD, or systemic immune dysregulation accompanies the injury being treated. See the KLOW article for full details.

Evidence Highlights

  • GHK-Cu genomic data (PMC, 2018): GHK-Cu modulates over 4,000 human genes, including 31 of 66 genes linked to chronic destructive conditions, shifting them toward repair programs.
  • TB-500 multi-tissue review (Goldstein, 2015): Documented repair in muscle, tendon, cornea, cardiac, and neural tissue. TB-500 provides systemic breadth to GLOW.
  • BPC-157 orthopaedic review (PMC, 2025): 35 preclinical studies demonstrating tendon, muscle, bone, and cartilage repair. BPC-157 delivers targeted local healing within GLOW.
  • GHK-Cu human wound data (Mulder et al., 1994): Multicenter RCT showing improved closure of diabetic foot ulcers with GHK-Cu gel. Human proof-of-concept for the dominant GLOW component.

Next Steps

Leave a comment